Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN510 + KN713 in Advanced Solid Tumors
NCT06012708Phase 1Completed
- Sponsor
- New Cancer Cure-Bio Co., Ltd
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KN-510 and KN713 in solid tumor (advanced stage) (4 arms), sponsored by New Cancer Cure-Bio Co., Ltd. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events up to 5 months and 3 more. Started Sep 2023; status: completed.
02
Drugs
KN-510KN713
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06012708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06012708.